SEP
JAZZ icon

Signature Equity Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Signature Equity Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Hold
751
– – 0.08% 236
2025
Q4 		$128K Buy
+751
New +$115K 0.07% 232

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Signature Equity Partners's JAZZ Position: Q1 2026 in Review

Signature Equity Partners held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 751 shares worth $142K. The position accounts for 0.08% of the portfolio, ranked #236.

Signature Equity Partners first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Signature Equity Partners held 751 shares of Jazz Pharmaceuticals worth $142K as of Q1 2026.
  • Signature Equity Partners left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
  • Jazz Pharmaceuticals made up 0.08% of Signature Equity Partners's portfolio in Q1 2026, its #236 holding.
  • Signature Equity Partners first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.